Copy to clipboard 
DJO Global posted 3Q17 revenue of US $290.9MM, +1.3% vs. 3Q16, and YTD revenue of $873.9MM, +1.7% vs. the prior year.
ORTHOWORLD estimates segment sales and growth as follows.
| 3Q17 | 3Q16 | $ Change | % Change | |
| Joint Reconstruction | $61.7 | $50.2 | $11.5 | 22.9% |
| Knee | $16.7 | $13.5 | $3.2 | 23.8% |
| Hip | $14.5 | $11.7 | $2.8 | 24.2% |
| Extremities | $30.5 | $25.0 | $5.5 | 21.8% |
| Other* | $229.2 | $237.0 | -$7.8 | -3.3% |
| Total | $290.9 | $287.2 | $3.7 | 1.3% |
| 9Mo17 | 9Mo16 | $ Change | % Change | |
| Joint Reconstruction | $182.7 | $151.6 | $31.1 | 20.5% |
| Knee | $48.9 | $39.9 | $9.0 | 22.5% |
| Hip | $43.6 | $34.6 | $9.0 | 25.9% |
| Extremities | $90.2 | $77.1 | $13.1 | 17.0% |
| Other* | $691.3 | $707.4 | -$16.1 | -2.3% |
| Total | $873.9 | $858.9 | $15.0 | 1.7% |
*Includes Bracing/Vascular, Recovery Sciences and also International revenue not already attributed to Joint Recon
As in the 2Q17 call, not much time was spent in direct commentary on the orthopaedic segment, though it was reiterated that the Surgical Implant business should continue to be a significant, profitable, long-term growth driver. Weather was cited as having a -$1MM impact on the quarter; many of those cases are expected to be rescheduled.
More time was spent on the business transformation initiative, which encompasses the whole company. Specific impact on joint reconstruction has not been separated out, but we can generally affirm that:
- DJO finds itself on track to achieve 7% to 10% cost savings by the end of 2018
- They continue to pursue the goal of reducing SKUs from 44,000 to 22,000 at the end of 2017 (again—I have not located information to indicate which business segments are affected); for SKUs to-be-eliminated, upstream supply chain processes are shut down and inventory levels being sold through
- At the close of 3Q, the company was down net 130+ professional staff vs. year-end 2016; five new business process outsourcing partners have onboarded over 500 new employees, and DJO is now processing many of its transactions through those centers (such as finance, accounting,customer care, sales, IT, Office Care reimbursement, etc.), focusing on centralization, standardization, automation and modernization of processes
The transformation initiative, launched in 2017, seeks to deliver productivity improvements throughout the company.
Sources: DJO Global; ORTHOWORLD Inc. estimates
DJO Global posted 3Q17 revenue of US $290.9MM, +1.3% vs. 3Q16, and YTD revenue of $873.9MM, +1.7% vs. the prior year.
ORTHOWORLD estimates segment sales and growth as follows.
Q17
Q16
$ Change
% Change
Joint...
DJO Global posted 3Q17 revenue of US $290.9MM, +1.3% vs. 3Q16, and YTD revenue of $873.9MM, +1.7% vs. the prior year.
ORTHOWORLD estimates segment sales and growth as follows.
| 3Q17 | 3Q16 | $ Change | % Change | |
| Joint Reconstruction | $61.7 | $50.2 | $11.5 | 22.9% |
| Knee | $16.7 | $13.5 | $3.2 | 23.8% |
| Hip | $14.5 | $11.7 | $2.8 | 24.2% |
| Extremities | $30.5 | $25.0 | $5.5 | 21.8% |
| Other* | $229.2 | $237.0 | -$7.8 | -3.3% |
| Total | $290.9 | $287.2 | $3.7 | 1.3% |
| 9Mo17 | 9Mo16 | $ Change | % Change | |
| Joint Reconstruction | $182.7 | $151.6 | $31.1 | 20.5% |
| Knee | $48.9 | $39.9 | $9.0 | 22.5% |
| Hip | $43.6 | $34.6 | $9.0 | 25.9% |
| Extremities | $90.2 | $77.1 | $13.1 | 17.0% |
| Other* | $691.3 | $707.4 | -$16.1 | -2.3% |
| Total | $873.9 | $858.9 | $15.0 | 1.7% |
*Includes Bracing/Vascular, Recovery Sciences and also International revenue not already attributed to Joint Recon
As in the 2Q17 call, not much time was spent in direct commentary on the orthopaedic segment, though it was reiterated that the Surgical Implant business should continue to be a significant, profitable, long-term growth driver. Weather was cited as having a -$1MM impact on the quarter; many of those cases are expected to be rescheduled.
More time was spent on the business transformation initiative, which encompasses the whole company. Specific impact on joint reconstruction has not been separated out, but we can generally affirm that:
- DJO finds itself on track to achieve 7% to 10% cost savings by the end of 2018
- They continue to pursue the goal of reducing SKUs from 44,000 to 22,000 at the end of 2017 (again—I have not located information to indicate which business segments are affected); for SKUs to-be-eliminated, upstream supply chain processes are shut down and inventory levels being sold through
- At the close of 3Q, the company was down net 130+ professional staff vs. year-end 2016; five new business process outsourcing partners have onboarded over 500 new employees, and DJO is now processing many of its transactions through those centers (such as finance, accounting,customer care, sales, IT, Office Care reimbursement, etc.), focusing on centralization, standardization, automation and modernization of processes
The transformation initiative, launched in 2017, seeks to deliver productivity improvements throughout the company.
Sources: DJO Global; ORTHOWORLD Inc. estimates
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.
